Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We describe three cases of critical acute myositis with myocarditis occurring within 22 days of each other at a single institution, all within 1 month of receiving the initial cycle of the anti-PD-1 drug pembrolizumab. Analysis of T cell receptor repertoires from peripheral blood and tissues revealed a high degree of clonal expansion and public clones between cases, with several T cell clones expanded within the skeletal muscle putatively recognizing viral epitopes. All patients had recently received a COVID-19 mRNA booster vaccine prior to treatment and were positive for SARS-CoV2 Spike antibody. In conclusion, we report a series of unusually severe myositis and myocarditis following PD-1 blockade and the COVID-19 mRNA vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11043765 | PMC |
| http://dx.doi.org/10.1136/jitc-2023-008151 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study.
Eur Heart J
August 2025
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe PEPITES, 47 Boulevard de l'Hopital, Paris 75013, France.
Background And Aims: Immune checkpoint inhibitor (ICI)-induced (cardio)-myotoxicities, including myocarditis and myositis, are uncommon but frequently severe adverse drug reactions seen in cancer patients. Real-life ICI myotoxicity incidence estimates span from limited-size cohorts, with risk factors and prognosticators poorly established, as well as their impact on survival.
Methods: This retrospective French National Health Data System cohort study included all adult patients starting ICI between 1 January 2012 and 30 September 2022.
[Clinical characteristics and prognosis of immune checkpoint inhibitor-associated myasthenia gravis].
Zhonghua Yi Xue Za Zhi
September 2025
Department of Neurology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450003, China.
The clinical data and follow-up outcomes of 9 patients diagnosed with immune checkpoint inhibitor (ICI)-associated myasthenia gravis (MG) admitted to Henan Provincial People's Hospital from January 2021 to October 2024 were collected retrospectively to analyze their clinical characteristics and prognosis. Nine patients were enrolled, including 4 males and 5 females, aged [ (, )] 69 (55, 77) years. All patients had tumors and had received ICI treatment.
View Article and Find Full Text PDFGene therapy for Duchenne muscular dystrophy.
Brain Dev
August 2025
Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.. Electronic address:
Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disorder caused by variants of the DMD that leads to progressive muscle degeneration. Recent advances in gene therapy have opened new therapeutic avenues, particularly through the use of adeno-associated virus (AAV)-mediated micro-dystrophin delivery. Delandistrogene moxeparvovec, the first FDA-approved gene therapy for DMD, has demonstrated transgene expression and potential functional improvement in early phase trials, although its long-term efficacy, durability, and safety remain unconfirmed.
View Article and Find Full Text PDFImmune Checkpoint Inhibitor-Induced Myositis Myocarditis and Myasthenia Gravis (MMM) Overlap Syndrome in a Rural District General Hospital: An Institutional Case Series Involving Four Patients.
Cureus
August 2025
Acute Oncology, Hywel Dda University Health Board, Haverfordwest, GBR.
Immune checkpoint inhibitors (ICIs) are commonly used for the treatment of some advanced cancers. Although effective, they can cause side effects. This case series describes four patients treated for ICI-induced myositis, myocarditis and myasthenia gravis (MMM) overlap syndrome at a rural general hospital in the United Kingdom between 2023 and 2025.
View Article and Find Full Text PDFMyocarditis, Myositis, and Myasthenia Gravis: The Complexities of Treating Steroid-Refractory Triple M Syndrome.
JACC Case Rep
August 2025
Division of Cardiology, Department of Medicine, Northwestern University, Chicago, Illinois, USA. Electronic address:
Background: Triple M syndrome is the combination of myocarditis, myositis, and myasthenia gravis secondary to immune checkpoint inhibitor (ICI) treatment. Traditionally managed with high-dose steroids, ICI myocarditis may benefit from early initiation of nonsteroidal immunosuppression.
Case Summary: A man with hepatocellular carcinoma presented with double vision and an elevated high-sensitivity troponin after receiving his first dose of tremelimumab (CTLA-4 inhibitor) and durvalumab (PD-L1 inhibitor).